Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
¹ ФГБОУ ВО СПбГУ, кафедра психиатрии и наркологии; 2 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1; 3 компания ЗАО «ФармФирма Сотекс»; 4 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беэр-Шева; 5 ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310.
Список исп. литературыСкрыть список 1. Беккер Р.А., Быков Ю.В. Тревожные и диссомнические депрессии: клиника, диагностика, терапия и эффективность препарата Рокона® (флувоксамин). Психиатрия и психофармакотерапия им. П. Б. Ганнушкина.2019;21(3):17-23. 2. Беккер Р.А, Быков Ю.В. Флувоксамин: антидепрессант широкого спектра с рядом особенностей и преимуществ (обзор литературы). Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2019;21(1):11-26. 3. Морозов П.В, Петрова Н.Н. О подходах к терапии и предупреждению обсессивно-компульсивных расстройств (ОКР) в период пандемии COVID-19 (обзор международных рекомендаций). Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2020;02:37-40. 4. Мосолов С.Н. Проблемы психического здоровья в условиях пандемии COVID-19. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(5):7-15. DOI: 10.17116/jnevro20201200517. 5. Ahorsu DK, Lin CY, Pakpour AH. The Association Between Health Status and Insomnia, Mental Health, and Preventive Behaviors: The Mediating Role of Fear of COVID-19. Gerontol Geriatr Med. 2020;6: 2333721420966081. DOI: 10.1177/2333721420966081. 6. Albayrak Y, Hashimoto K. Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders. Adv Exp Med Biol. 2017;964:153-161. DOI: 10.1007/978-3-319-50174-1_11. 7. Aleebrahim-Dehkordi E, Soveyzi F, Deravi N et al. Human coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in children. J Pediatr Nurs. 2020;56:70-79. DOI: 10.1016/j.pedn.2020.10.020. 8. Al-Samkari H, Leaf RK, Dzik WH et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500. DOI: 10.1182/blood.2020006520. 9. Altschuler EL, Kast RE. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS). Med Hypotheses. 2020;141:109774. DOI: 10.1016/j.mehy.2020.109774. 10. Amraei R, Rahimi N. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Cells. 2020;9(7):1652. DOI: 10.3390/cells9071652. 11. Anderson G, Reiter RJ. Melatonin: Roles in influenza, Covid-19, and other viral infections. Rev Med Virol. 2020;30(3):e2109. DOI: 10.1002/rmv.2109. 12. Arshad S, Kilgore P, Chaudhry ZS et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403. DOI: 10.1016/j.ijid.2020.06.099. 13. Bikdeli B, Madhavan MV, Jimenez D et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. 14. Canli T. A model of human endogenous retrovirus (HERV) activation in mental health and illness. Med Hypotheses. 2019;133:109404. DOI: 10.1016/j.mehy.2019.109404. 15. Canli T. Reconceptualizing major depressive disorder as an infectious disease. Biol Mood Anxiety Disord. 2014;4:10. DOI: 10.1186/2045-5380-4-10. 16. Caruso A, Caccuri F, Bugatti A et al. Methotrexate inhibits SARS-CoV-2 virus replication "in vitro". J Med Virol. 2020. DOI: 10.1002/jmv.26512. 17. Chaná-Cuevas P, Salles-Gándara P, Rojas-Fernandez A et al. The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson's Disease. Front Neurol. 2020;11:1044. DOI: 10.3389/fneur.2020.01044. 18. Choi EH, Hui BH, Wan EF. Depression and Anxiety in Hong Kong during COVID-19. Int J Environ Res Public Health. 2020;17(10):3740. DOI: 10.3390/ijerph17103740. 19. Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020;35:100684. DOI: 10.1016/j.nmni. 2020.100684. 20. Chow JH, Khanna AK, Kethireddy S et al. Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19. Anesth Analg. 2020. DOI: 10.1213/ANE.0000000000005292. 21. Cobos EJ, Entrena JM, Nieto FR et al. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol. 2008;6(4):344-366. DOI: 10.2174/157015908787386113. 22. Czeisler ME, Lane RI, Petrosky E et al. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049-1057. DOI: 10.15585/mmwr.mm6932a1. 23. Davies J, Randeva HS, Chatha K et al. Neuropilin‑1 as a new potential SARS‑CoV‑2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID‑19. Mol Med Rep. 2020;22(5):4221-4226. DOI: 10.3892/mmr.2020.11510. 24. Demisch K, Demisch L, Nickelsen T et al. The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine. J Neural Transm. 1987;68(3-4):257-270. DOI: 10.1007/BF02098502. 25. Farouk A, Salman S. Dapsone and doxycycline could be potential treatment modalities for COVID-19. Med Hypotheses. 2020;140:109768. DOI: 10.1016/j.mehy.2020.109768. 26. Figueroa CA, Aguilera A. The Need for a Mental Health Technology Revolution in the COVID-19 Pandemic. Front Psychiatry. 2020;11:523. DOI: 10.3389/fpsyt.2020.00523. 27. Flacco ME, Martellucci CA, Bravi F et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020;106(19):1519-1524. DOI: 10.1136/heartjnl-2020-317336. 28. Frohman EM, Villemarette-Pittman NR, Cruz RA et al. Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack. J Neurol Sci. 2020;415:116935. DOI: 10.1016/j.jns.2020.116935. 29. Gale SD, Berrett AN, Erickson LD et al. Association between virus exposure and depression in US adults. Psychiatry Res. 2018;261:73-79. DOI: 10.1016/j.psychres.2017.12.037. 30. García IG, Rodriguez-Rubio M, Mariblanca AR et al. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):466. DOI: 10.1186/s13063-020-04436-6. 31. Gautam SS, Gautam CS, Garg VK et al. Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. Expert Rev Clin Pharmacol. 2020;13(11):1183-1190. DOI: 10.1080/17512433.2020.1832889. 32. Gautret P, Lagier JC, Parola P et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020;34:101663. DOI: 10.1016/j.tmaid.2020.101663. 33. Giménez VM, Inserra F, Tajer CD et al. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment. Life Sci. 2020;254:117808. DOI: 10.1016/j.lfs.2020.117808. 34. Gomeni R, Xu T, Gao X et al. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2. J Pharmacokinet Pharmacodyn. 2020;47(3): 189-198. DOI: 10.1007/s10928-020-09690-4. 35. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. 36. Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine. 2020;100591. DOI: 10.1016/j.eclinm.2020.100591. 37. Härtter S, Grözinger M, Weigmann H et al. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther. 2000;67(1):1-6. DOI: 10.1067/mcp.2000.104071. 38. Härtter S, Wang X, Weigmann H et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001;21(2):167-74. DOI: 10.1097/00004714-200104 000-00008. 39. Hippisley-Cox J, Young D, Coupland С et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020;106(19):1503-1511. DOI: 10.1136/heartjnl-2020-317393. 40. Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents. 2020;56(2):106044. DOI: 10.1016/j.ijantimicag.2020.106044. 41. https://www.covid19‐druginteractions.org Информация о взаимодействии противовирусных лекарств с психотропными и другими препаратами с сайта отделения клинической фармакологии Ливерпульского университета. Адаптировано С.Н. Мосоловым для РФ в 2020 г. Доступ проверен 18.11.2020 г. 42. https://www.kff.org/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-... Отчет KFF о последствиях COVID-19 для психического и наркологического здоровья популяции. Опубликовано 21.09.2020. Доступ проверен 18.11.2020. 43. Hu K, Wang M, Zhao Y et al. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. Virol Sin. 2020;1-9. DOI: 10.1007/s12250-020-00258-7. 44. Javanmard SH, Heshmat-Ghahdarijani K, Vaseghi G. Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox. Infect Control Hosp Epidemiol. 2020;1-2. DOI: 10.1017/ice.2020.195. 45. Karampela I, Dalamaga M. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? Arch Med Res. 2020;51(7):741-742. DOI: 10.1016/j.arcmed.2020.06.004. 46. Kornhuber J, Muehlbacher M, Trapp S et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8):e23852. DOI: 10.1371/journal.pone.0023852. 47. Le HT, Lai AX, Sun J et al. Anxiety and Depression Among People Under the Nationwide Partial Lockdown in Vietnam. Front Public Health. 2020;8:589359. DOI: 10.3389/fpubh.2020.589359. 48. Lee SA, Jobe MC, Mathis AA et al. Incremental validity of coronaphobia: Coronavirus anxiety explains depression, generalized anxiety, and death anxiety. J Anxiety Disord. 2020;74:102268. DOI: 10.1016/j.janxdis.2020.102268. 49. Lee SW, Yang JM, Moon SY et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020;S2215-0366(20)30421-1. DOI: 10.1016/S2215-0366(20)30421-1. 50. Lenze EJ, Mattar C, Zorumski CF et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020;e2022760. DOI: 10.1001/jama. 2020.22760. 51. Liu C, von Brunn A, Zhu D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med Drug Discov. 2020;7:100056. DOI: 10.1016/j.medidd.2020.100056. 52. Marciniec K, Beberok A, Pęcak P et al. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. Pharmacol Rep. 2020;1-9. DOI: 10.1007/s43440-020-00169-0. 53. Marinella MA. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. Int J Clin Pract. 2020;74(9):e13535. DOI: 10.1111/ijcp.13535. 54. Marshall M. How COVID-19 can damage the brain. Nature. 2020;585(7825):342-343. DOI: 10.1038/d41586-020-02599-5. 55. Mattos-Silva P, Felix NS, Silva PL et al. Pros and cons of corticosteroid therapy for COVID-19 patients. Respir Physiol Neurobiol. 2020;280:103492. DOI: 10.1016/j.resp.2020.103492. 56. McFee RB. COVID-19: Therapeutics and interventions currently under consideration. Dis Mon. 2020;101058. DOI: 10.1016/j.disamonth.2020. 101058. 57. Mishra R, Banerjea AC. Neurological Damage by Coronaviruses: A Catastrophe in the Queue! Front Immunol. 2020;11:565521. DOI: 10.3389/fimmu.2020.565521. 58. Nanda S, Handa R, Prasad A, Anand R et al. Covid-19 associated Guillain-Barre Syndrome: Contrasting tale of four patients from a tertiary care centre in India. Am J Emerg Med. 2020;S0735-6757(20)30823-8. DOI: 10.1016/j.ajem.2020.09.029. 59. Narita N, Hashimoto K, Tomitaka S et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307(1):117-119. DOI: 10.1016/0014-2999(96)00254-3. 60. Ozamiz-Etxebarria N, Dosil-Santamaria M, Picaza-Gorrochategui M et al. Stress, anxiety, and depression levels in the initial stage of the COVID-19 outbreak in a population sample in the northern Spain. Cad Saude Publica. 2020;36(4):e00054020. DOI: 10.1590/0102-311X00054020. 61. Özdin S, Özdin SB. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry. 2020;66(5):504-511. DOI: 10.1177/ 0020764020927051. 62. Öztürk G, Akbulut KG, Güney S. Melatonin, aging, and COVID-19: Could melatonin be beneficial for COVID-19 treatment in the elderly? Turk J Med Sci. 2020;50(6):1504-1512. DOI: 10.3906/sag-2005-356. 63. Pappa S, Ntella V, Giannakas T et al. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav Immun. 2020;88:901-907. DOI: 10.1016/j.bbi.2020.05.026. 64. Pierce M, Hope H, Ford T et al. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. Lancet Psychiatry. 2020;7:883-892. DOI: 10.1016/S2215-0366(20)30308-4. 65. Phadke M, Saunik S. COVID-19 treatment by repurposing drugs until the vaccine is in sight. Drug Dev Res. 2020 Aug;81(5):541-543. doi: 10.1002/ddr.21666. 66. Reger MA, Stanley IH, Joiner TE. Suicide Mortality and Coronavirus Disease 2019-A Perfect Storm? JAMA Psychiatry. 2020. DOI: 10.1001/jamapsychiatry.2020.1060. 67. Revannasiddaiah S, Devadas SK, Palassery R et al. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2. Med Hypotheses. 2020;144:109850. DOI: 10.1016/j.mehy.2020.109850. 68. Rogers JP, Chesney E, Oliver D et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611-627. DOI: 10.1016/S2215-0366(20)30203-0. 69. Rosen DA, Seki SM, Fernández-Castañeda A et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11(478):eaau5266. DOI: 10.1126/scitranslmed.aau5266. 70. Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife. 2020;9:e57278. DOI: 10.7554/eLife.57278. 71. Rudnicka L, Glowacka P, Goldust M et al. Cyclosporine therapy during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(2):e151-e152. DOI: 10.1016/j.jaad.2020.04.153. 72. Schloer S, Brunotte L, Goretzko J et al. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect. 2020;9(1):2245-2255. DOI: 10.1080/22221751. 2020.1829082. 73. Schnittker J. In-utero determinants of adult depression: evidence from the 1918 flu pandemic. Biodemography Soc Biol. 2020;65(3):227-244. DOI: 10.1080/19485565.2020.1744424. 74. Schön MP, Berking C, Biedermann T et al. COVID-19 and immunological regulations - from basic and translational aspects to clinical implications. J Dtsch Dermatol Ges. 2020;10.1111/ddg.14169. DOI: 10.1111/ddg.14169. 75. Seif F, Aazami H, Khoshmirsafa M et al. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Int Arch Allergy Immunol. 2020;181(6):467-475. DOI: 10.1159/000508247. 76. Seif F, Pornour M, Mansouri D. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19. Int Arch Allergy Immunol. 2020;181(8):648-649. DOI: 10.1159/000509198. 77. Singh H, Kakkar AK, Chauhan P. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges. Expert Rev Anti Infect Ther. 2020;18(10):997-1003. DOI: 10.1080/14787210. 2020.1782190. 78. S.B. Smith, T.-P. Su (eds.), Sigma Receptors: Their Role in Disease and as Therapeutic Targets, 2017, Advances in Experimental Medicine and Biology 964, DOI 10.1007/978-3-319-50174-1_11 79. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084-H1090. DOI: 10.1152/ajpheart.00217.2020. 80. Stanton R, To QG, Khalesi S et al. Depression, Anxiety and Stress during COVID-19: Associations with Changes in Physical Activity, Sleep, Tobacco and Alcohol Use in Australian Adults. Int J Environ Res Public Health. 2020;17(11):4065. DOI: 10.3390/ijerph17114065. 81. Stein MB. COVID-19 and Anxiety and Depression in 2020. Depress Anxiety. 2020;37:302. DOI: 10.1002/da.22870. 82. Tomazini BM, Maia IS, Cavalcanti AB et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307-1316. DOI: 10.1001/jama.2020.17021. 83. Tsai YC, Tsai TF. Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review. Ther Adv Musculoskelet Dis. 2020;12:1759720X20947296. DOI: 10.1177/1759720X20947296. 84. Ugurel OM, Mutlu O, Sariyer E et al. Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13). Int J Biol Macromol. 2020;163:1687-1696. DOI: 10.1016/j.ijbiomac.2020.09.138. 85. Uyaroğlu OA, Güven GS, Güllü I. Can Levamisole be used in the treatment of COVID-19 patients presenting with diarrhea? J Infect Dev Ctries. 2020;14(8):844-846. DOI: 10.3855/jidc.13101. 86. von Bahr C, Ursing C, Yasui N et al. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol. 2000;56(2):123-127. DOI: 10.1007/s002280050729. 87. Wadoo O, Latoo J, Reagu SM et al. Mental health during COVID-19 in Qatar. Gen Psychiatr. 2020;33(6):e100313. DOI: 10.1136/gpsych-2020-100313. 88. Wang M, Zhao Y, Hu W et al. Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide - a Single-Center, Randomized, Controlled Clinical Trial. Clin Infect Dis. 2020;ciaa1417. DOI: 10.1093/cid/ciaa1417. 89. Yesilkaya UH, Balcioglu YH, Sahin S. Reissuing the sigma receptors for SARS-CoV-2. J Clin Neurosci. 2020;80:72-73. DOI: 10.1016/j.jocn. 2020.08.014. 90. Zhang R, Wang X, Ni L et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583. DOI: 10.1016/j.lfs.2020.117583. 91. Zhang WR, Wang KW, Yin L et al. Mental Health and Psychosocial Problems of Medical Health Workers during the COVID-19 Epidemic in China. Psychother Psychosom. 2020;89(4):242-250. DOI: 10.1159/000507639. 92. Zhang X, Li S, Niu S. ACE2 and COVID-19 and the resulting ARDS. Postgrad Med J. 2020;96(1137):403-407. DOI: 10.1136/postgradmedj-2020-137935.